Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.54 |
| ▸ | JAK3 | P52333 | 8/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12921688 | 0.95 | JAK2 (0.51) | JAK2JAK3TYK2JAK1SMG1 | |
| SCHEMBL12948473 | 0.92 | JAK2 (0.54) | JAK2JAK3TYK2JAK1CAMK2D | |
| SCHEMBL12948324 | 0.91 | JAK2 (0.49) | JAK2JAK3TYK2JAK1SMG1 | |
| SCHEMBL12921711 | 0.90 | JAK2 (0.48) | JAK2JAK3TYK2JAK1SMG1 | |
| SCHEMBL12948482 | 0.89 | JAK2 (0.47) | JAK2JAK3TYK2JAK1SMG1 | |
| SCHEMBL12921689 | 0.88 | JAK2 (0.48) | JAK2JAK3TYK2JAK1SMG1 | |
| SCHEMBL12921690 | 0.85 | JAK2 (0.46) | JAK2JAK3TYK2JAK1SMG1 | |
| SCHEMBL12948369 | 0.84 | JAK2 (0.51) | JAK2JAK3TYK2JAK1CAMK2D | |
| SCHEMBL12921700 | 0.84 | JAK2 (0.56) | JAK2JAK3TYK2JAK1SMG1 | |
| SCHEMBL12921635 | 0.84 | JAK2 (0.51) | JAK2JAK3TYK2JAK1CAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-28 | — | — | US | disclosed |
| US-8318929-B2 | 4-aryl-2-anilino-pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | JAK2 372/4885JAK3 462/4885TYK2 81/4885 |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | JAK2 372/4885JAK3 462/4885TYK2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.